First-in-man clinical study of SCMod1 [Modi-1] for cancer
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs SCMod1 (Primary)
- Indications Breast cancer; Endometrial cancer; Osteosarcoma; Ovarian cancer
- Focus Adverse reactions; First in man
- 16 Sep 2016 According to Scancell media release, enrolment for triple negative breast cancer, ovarian cancer and osteosarcoma expected to commence in early 2018.
- 27 Jan 2016 According to a Scancell media release, clinical studies are scheduled to start in 2017.
- 03 Oct 2013 New trial record